Rare disease companies develop diagnostics, therapies and research technologies for conditions affecting relatively small patient populations. Their work often focuses on inherited disorders, complex diagnostic pathways and diseases with limited or no existing treatment options.
This category includes companies working on:
Browse 141 UK rare disease companies below.
Molecular disease research spanning genetics, neurobiology and intracellular infections
Cambridge Institute for Medical Research is a University of Cambridge institute studying the molecular mechanisms of human disease. Researchers investigate protein folding, cellular quality control, membrane trafficking and organelle function, focusing on rare genetic disorders, neurological conditions and…
Clinical-stage biopharma developing treatments for cancer and rare diseases
Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need. Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis,…
Small activating RNA therapeutics for gene upregulation and disease
MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of underactive genes by activating transcription rather than silencing it. The approach targets diseases driven by loss of normal gene…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease. Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of…
Small molecule therapeutics targeting PDE4 enzymes in kidney disease
Mironid is a company developing first-in-class small molecule therapeutics for autosomal dominant polycystic kidney disease, one of the most common hereditary kidney disorders. Its lead programme targets long-form PDE4 enzymes to modulate cyclic AMP signalling, the central driver of cyst growth across all disease…
Specialist AAV vector manufacturer for gene therapy developers
Trisk Bio is a contract development and manufacturing organisation specialising in the production of adeno-associated virus vectors for gene therapy applications. Its intensified manufacturing processes use suspension bioreactors and chromatography-based purification to deliver high-purity AAV at scalable yields for…
Clinical research organisation offering trial delivery and functional outsourcing services
Advanced Clinical is a clinical research organisation supporting biopharmaceutical and medical device companies through full-service and functional service provider models. It provides clinical trial management, site monitoring, quality and validation services and strategic resourcing, placing specialist clinical…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people worldwide for which no disease-modifying treatment currently exists. Its lead programme, Rincell-1, is an otic neural progenitor cell therapy…
Small molecule drugs targeting astrocytes in neurodegenerative disease
AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's approach targets astrocytes, brain support cells whose dysregulated inflammatory activity contributes to neurodegeneration, aiming to restore normal…
Full-service CRO for Phase I–IV pharmaceutical and device trials
Clinicology is a contract research organisation providing clinical trial management services to pharmaceutical, biotechnology, and medical device companies. Services span site startup, monitoring, project management, regulatory submissions, patient recruitment, medical monitoring, medical writing, and…
E3 ligase inhibitors stabilising tumour suppressor proteins
Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular…
Non-viral gene therapy platform enabling durable nuclear DNA delivery
Gramics Bio develops a gene therapy platform solving a key limitation of lipid nanoparticle delivery: enabling therapeutic DNA to reach the cell nucleus for durable expression without viral vectors. By programming specificity into synthetic DNA sequences rather than new delivery chemistries, the technology combines…
Specialist pharma acquiring and developing rare disease therapeutics
Ambrose Healthcare is a UK specialist pharmaceutical company developing treatments for rare diseases and patients in hospital and specialist care settings. The company builds its pipeline through the acquisition and licensing of late-stage clinical assets with existing human safety and efficacy data, targeting…
Oral small molecule therapies for rare hereditary diseases
KalVista Pharmaceuticals is a biopharmaceutical company specialising in the discovery and commercialisation of oral small molecule protease inhibitors for rare diseases with significant unmet need. The company's lead programme targets the kallikrein-kinin system and has produced an approved oral on-demand therapy for…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Synthetic platform for precision delivery of biologics in tissue repair
Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable,…